Virus inactivator composition, virus inactivation efficacy enhancing method, and virus inactivation method

Abstract

A virus inactivator composition, characterized in that it contains: (a) 0.01% to 5.0% by mass of a cationic virus inactivating component as a virus inactivating component; (b) 0.02% to 10.0% by mass of one or more selected from fumaric acid, phosphoric acid, lactic acid and citric acid as a virus inactivation efficacy enhancing component; and water.

Description

Technical Field

[0001] The present invention relates to a virucidal agent composition excellent in quick-acting property in virus inactivation, a method for enhancing virus inactivation efficacy, and a virus inactivation method. Background Art

[0002] Since the frequent occurrence of food poisoning incidents caused by Escherichia coli O-157, and then the rampant spread of SARS, a novel type of pneumonia, food poisoning caused by norovirus has occurred frequently in recent years. On the other hand, in the spring of 2009, a novel influenza occurred and was on the verge of a pandemic, increasing the concern about disinfection and hygiene. After 1996 when food poisoning incidents caused by Escherichia coli O-157 occurred frequently, many household products were used to impart antibacterial properties, and among the agents used, those using metal compounds such as silver and copper were more common. For example, antibacterial fibers containing salts of silver bromide or iodine complexes are known (Patent Document 1), but their mildew-proof effect is small and their effect on viruses is also insufficient.

[0003] On the other hand, several products that promote antiviral agents or antiviral effects have also been proposed. For example, there are known fibers coated or mixed with an antiviral agent containing a water-insoluble aromatic hydroxy compound having a phenolic hydroxyl group at at least one site (Patent Document 2), a fiber antiviral processing agent containing polyoxyethylene (dimethylimino) ethylene (dimethylimino) ethylene dichloride (Patent Document 3), zinc 2-pyridinethiol-1-oxide, copper 2-pyridinethiol-1-oxide, or antiviral fibers treated with an antiviral agent containing both of them (Patent Document 4), etc.

[0004] In addition, the present applicant focused on 1,4-bis(3,3'-(1-decylpyridinium)methoxy)dibromobutane and found that this compound is also specifically effective against norovirus (Patent Document 5). The norovirus inactivator of Patent Document 5 is excellent, but there is still room for research to improve its performance in terms of quick-acting property in virus inactivation.

[0005] Especially in recent years, with the prevalence of infectious diseases such as the novel coronavirus, the opportunity for daily disinfection has increased. Therefore, improving the quick-acting property in virus inactivation is also related to shortening the time consumed by users for disinfection, and thus is an important issue.

[0006] Prior Art Documents

[0007] Patent Documents

[0008] Patent Document 1: Japanese Patent Laid-Open No. 2008-338481

[0009] Patent Document 2: Japanese Patent Laid-Open No. 2005-112748

[0010] Patent Document 3: Japanese Patent Application Publication No. 2008-115506

[0011] Patent Document 4: Japanese Patent Application Publication No. 2009-7736

[0012] Patent Document 5: Japanese Patent No. 5377098 Summary of the invention

[0013] Problems to be solved by the invention

[0014] An object of the present invention is to provide a virus inactivating agent composition having excellent rapid effect in virus inactivation, a method for enhancing virus inactivation efficacy, and a virus inactivation method.

[0015] Means used to solve problems

[0016] In order to achieve the above-mentioned object, the present invention is a virus inactivator composition, characterized in that it contains: (a) 0.01 mass % to 5.0 mass % of a cationic virus inactivating component as a virus inactivating component; (b) 0.02 mass % to 10.0 mass % of one or more selected from fumaric acid, phosphoric acid, lactic acid and citric acid as a virus inactivation efficacy enhancing component; and water.

[0017] In addition, the present invention is characterized in that, in the virus inactivating agent composition having the above-mentioned structure, the cationic virus inactivating component is one or more selected from dialkyldimethylammonium salts (wherein the alkyl groups are the same or different and represent a straight-chain saturated hydrocarbon having 8 to 20 carbon atoms), trialkyl(3-triethoxysilylpropyl)ammonium salts (wherein the alkyl groups are the same or different and represent a straight-chain saturated hydrocarbon having 1 to 18 carbon atoms), 1,4-bis(3,3'-(1-decylpyridinium)methoxy)butane salts, benzalkonium salts, benzyloxyethylammonium salts, and chlorhexidine salts.

[0018] In addition, the present invention is characterized in that, in the virus inactivator composition having the above-mentioned structure, the cationic virus inactivating component is one or more selected from 1,4-bis(3,3'-(1-decylpyridinium)methoxy)dibromobutane, benzalkonium chloride, benzethonium chloride, didecyldimethylammonium chloride, chlorhexidine digluconate and octadecyldimethyl(3-triethoxysilylpropyl)ammonium chloride.

[0019] The present invention is also characterized in that the virus inactivating agent composition having the above-mentioned structure further comprises (c) 10% to 80% by mass of ethanol.

[0020] The present invention is also characterized in that, in the virus inactivating agent composition having the above-mentioned structure, the blending amount of the above-mentioned (c) ethanol is 35% by mass to 65% by mass.

[0021] The present invention is also characterized in that, in the virus inactivating agent composition having the above-mentioned structure, the blending mass ratio (a) / (b) of the above-mentioned virus inactivating efficacy enhancing component (b) to the above-mentioned virus inactivating component (a) is 0.001≤(a) / (b)≤250.

[0022] In addition, the present invention is a method for enhancing virus inactivation efficacy, characterized in that 0.02% to 10.0% by mass of one or more selected from fumaric acid, phosphoric acid, lactic acid and citric acid is added as (b) a virus inactivation efficacy enhancing component to a virus inactivator composition containing 0.01% to 5.0% by mass of a cationic virus inactivating component as (a) a virus inactivating component and water.

[0023] In addition, the present invention is a method for inactivating a non-enveloped virus, comprising contacting the virus inactivating agent composition having the above-mentioned structure with a non-enveloped virus.

[0024] Effects of the Invention

[0025] According to the first configuration of the present invention, by blending 0.01% by mass to 5.0% by mass of a cationic virus inactivating component as (a) a virus inactivating component, 0.02% by mass to 10.0% by mass of one or more selected from fumaric acid, phosphoric acid, lactic acid and citric acid as (b) a virus inactivation efficacy enhancing component, and water, a virus inactivating agent composition is obtained which has excellent feel during use, has no concern of skin irritation due to alkali, and has excellent rapidity in virus inactivation.

[0026] In addition, according to the second configuration of the present invention, in the virus inactivating agent composition of the first configuration, the cationic virus inactivating component uses one or more selected from dialkyldimethylammonium salts (wherein the alkyl groups are the same or different and represent a straight-chain saturated hydrocarbon having 8 to 20 carbon atoms), trialkyl(3-triethoxysilylpropyl)ammonium salts (wherein the alkyl groups are the same or different and represent a straight-chain saturated hydrocarbon having 1 to 18 carbon atoms), 1,4-bis(3,3'-(1-decylpyridinium)methoxy)butane salts, benzalkonium salts, benzyloxyethylammonium salts, and chlorhexidine salts, thereby providing a virus inactivating agent composition that can more effectively improve the rapid effect of virus inactivation.

[0027] In addition, according to the third configuration of the present invention, in the virus inactivator composition of the second configuration, the cationic virus inactivating component uses one or more selected from 1,4-bis(3,3'-(1-decylpyridinium)methoxy)dibromobutane, benzalkonium chloride, benzethonium chloride, didecyldimethylammonium chloride, chlorhexidine digluconate and octadecyldimethyl(3-triethoxysilylpropyl)ammonium chloride, thereby achieving a virus inactivator composition that can more effectively improve the rapid effect of virus inactivation.

[0028] In addition, according to the fourth configuration of the present invention, in the virus inactivator composition of any one of the first to third configurations, by adding 10% to 80% by mass of (c) ethanol, the rapidity of virus inactivation can be improved, and the dispersibility of the virus inactivator composition is also improved, thereby becoming a virus inactivator composition with excellent quick-drying properties.

[0029] In addition, according to the fifth configuration of the present invention, in the virus inactivator composition of the fourth configuration, by setting the blending amount of (c) ethanol to 35% by mass to 65% by mass, the rapid effect in virus inactivation can be more effectively improved, and skin irritation is less likely to occur during use. In addition, the dispersibility of the virus inactivator composition is also effectively improved, thereby achieving a virus inactivator composition with excellent quick-drying properties.

[0030] In addition, according to the sixth configuration of the present invention, in the virus inactivating agent composition of any one of the first to fifth configurations, the quick effect in virus inactivation can be further improved by setting the blending mass ratio (a) / (b) of the virus inactivating efficacy enhancing component (b) to the virus inactivating component (a) to 0.001≤(a) / (b)≤250.

[0031] In addition, according to the seventh configuration of the present invention, by adding 0.02% by mass to 10.0% by mass of one or two or more selected from fumaric acid, phosphoric acid, lactic acid and citric acid as (b) a virus inactivation efficacy enhancing component to a virus inactivator composition containing 0.01% by mass to 5.0% by mass of a cationic virus inactivating component as (a) a virus inactivating component and water, it is possible to produce a virus inactivator composition capable of improving the rapidity of the cationic virus inactivating component in virus inactivation.

[0032] According to the eighth aspect of the present invention, by bringing the virus inactivating agent composition of any one of the first to sixth aspects into contact with a non-enveloped virus, an effective method for inactivating non-enveloped viruses that have low drug sensitivity and are difficult to inactivate is achieved. DETAILED DESCRIPTION

[0033] Hereinafter, the virus inactivating agent composition of the present invention will be described in detail, but the present invention is not intended to be limited to the configurations described in the following embodiments and examples.

[0034] The virus inactivator composition of the present invention comprises: (a) 0.01% to 5.0% by mass of a cationic virus inactivating component as a virus inactivating component; (b) 0.02% to 10.0% by mass of one or more selected from fumaric acid, phosphoric acid, lactic acid and citric acid as a virus inactivation efficacy enhancing component; and water.

[0035] It is known that the (a) cationic virus inactivating component contained as a virus inactivating component in the virus inactivating composition of the present invention has a high virus inactivating effect, but there is still room for research on the rapidity of virus inactivation. This time, the present inventors have found for the first time that the rapidity of virus inactivation can be synergistically improved by using the (a) cationic virus inactivating component in combination with one or more selected from fumaric acid, phosphoric acid, lactic acid and citric acid.

[0036] In the virus inactivator composition of the present invention, in order to sufficiently improve the rapid effect in virus inactivation, the cationic virus inactivating component as (a) the virus inactivating component is blended in an amount of 0.01% by mass to 5.0% by mass relative to the entire virus inactivator composition. Here, the inactivating component is preferably blended in an amount of 0.05% by mass to 3.0% by mass, and more preferably blended in an amount of 0.10% by mass to 1.0% by mass.

[0037] Examples of the cationic virus inactivating component that is compounded as the (a) virus inactivating component in the virus inactivating agent composition of the present invention include quaternary ammonium salts, etc. The counter anions of the quaternary ammonium salts are not particularly limited, and examples thereof include fluoride ion, chloride ion, bromide ion, iodide ion, methosulfate ion, carbonate ion, bicarbonate ion, acetate ion, propionate ion, gluconate ion, etc.Specific examples of the quaternary ammonium salt include 1,4-bis[3,3′-(1-decylpyridinium)methoxy]butanedibromobutane, 1,4-bis[3,3′-(1-decylpyridinium)methoxy]butanedichlorobutane, 1,4-bis[3,3′-(1-decylpyridinium)methoxy]butanedimethylsulfate and other 1,4-bis[3,3′-(1-decylpyridinium)methoxy]butane salts, benzalkonium chloride, benzalkonium methylsulfate and other benzalkonium salts, benzethonium chloride, benzylethoxyammonium methylsulfate and other benzylethoxyammonium salts, cetylpyridinium chloride, cetylpyridinium methylsulfate and other cetylpyridinium salts, didecyldimethylammonium chloride, decyldimethylammonium methylsulfate and other dioctyldimethylammonium salts such as dioctyldimethylammonium chloride and dioctyldimethylammonium methylsulfate, dioctyldimethylammonium salts such as dioctyldimethylammonium chloride and dioctyldimethylammonium methylsulfate, dialkyldimethylammonium salts such as dioctyldimethylammonium chloride (wherein the alkyl groups are the same or different and represent a linear saturated hydrocarbon having 8 to 20 carbon atoms), N,N-didecyl-N-methylpoly(oxyethylene)ammonium salts such as N,N-didecyl-N-methylpoly(oxyethylene)ammonium propionate, N,N-didecyl-N,N-dimethylammonium carbonate / bicarbonate, N,N-didecyl -N,N-dimethylammonium chloride, chlorhexidine digluconate, chlorhexidine salts such as chlorhexidine hydrochloride, octadecyldimethyl(3-triethoxysilylpropyl)ammonium chloride, dodecyldimethyl(3-triethoxysilylpropyl)ammonium chloride, dodecyldiisopropyl(3-triethoxysilylpropyl)ammonium chloride, tetradecyldimethyl(3-triethoxysilylpropyl)ammonium chloride, tetradecyldiethyl(3-triethoxysilylpropyl)ammonium chloride, tetradecyldi-n-propyl(3-triethoxysilylpropyl)ammonium chloride, pentadecyldimethyl(3-triethoxysilylpropyl)ammonium chloride, pentadecyldiethyl(3- Trialkyl (3-triethoxysilylpropyl) ammonium salts (wherein the alkyl groups are the same or different and represent a linear saturated hydrocarbon having 1 to 18 carbon atoms) such as trialkyl (3-triethoxysilylpropyl) ammonium chloride, pentadecyl di-n-propyl (3-triethoxysilylpropyl) ammonium chloride, hexadecyl dimethyl (3-triethoxysilylpropyl) ammonium chloride, hexadecyl diethyl (3-triethoxysilylpropyl) ammonium chloride, hexadecyl di-n-propyl (3-triethoxysilylpropyl) ammonium chloride, octadecyl diethyl (3-triethoxysilylpropyl) ammonium chloride, and octadecyl di-n-propyl (3-triethoxysilylpropyl) ammonium chloride. These cationic virus inactivating components may be used alone or in combination of two or more.

[0038] From the viewpoint of being able to improve the rapid effect in virus inactivation, among the above-mentioned cationic virus inactivating components, 1,4-bis(3,3'-(1-decylpyridinium)methoxy)dibromobutane, benzalkonium chloride, benzethonium chloride, didecyldimethylammonium chloride, chlorhexidine digluconate and octadecyldimethyl(3-triethoxysilylpropyl)ammonium chloride are preferably used, and 1,4-bis(3,3'-(1-decylpyridinium)methoxy)dibromobutane is more preferably used.

[0039] As the organic acid and / or inorganic acid compounded as (b) the virus inactivation efficacy enhancing component in the virus inactivator composition of the present invention, one or more selected from fumaric acid, phosphoric acid, lactic acid, and citric acid can be cited, preferably one or more selected from fumaric acid, phosphoric acid, and lactic acid, preferably fumaric acid and / or phosphoric acid. By using these organic acids and / or inorganic acids, even if the cationic virus inactivating component as the virus inactivating component is compounded in a low amount, the rapidity of virus inactivation can be more significantly improved. These organic acids and / or inorganic acids can be used alone or in combination of two or more.

[0040] The pH of the virus inactivator composition of the present invention is preferably 1 to 6. This makes the virus inactivator composition acidic to weakly acidic, and less corrosive to the skin than alkaline virus inactivators, and provides a virus inactivator composition with excellent feel during use.

[0041] The amount of the virus inactivating efficacy enhancing component (b) in the virus inactivating composition of the present invention is not particularly limited, but if the amount is too small, the effect of sufficiently improving the rapidity of the cationic virus inactivating component in virus inactivation may not be obtained.

[0042] As shown in the Examples described below, in order to sufficiently improve the rapid effect in virus inactivation, the organic acid and / or inorganic acid as (b) the virus inactivation efficiency enhancing component is blended in an amount of 0.02 mass % to 10.0 mass % based on the virus inactivator composition, preferably 0.03 mass % to 5.0 mass % and more preferably 0.10 mass % to 2.0 mass % based on the virus inactivator composition.

[0043] In the virus inactivator composition of the present invention, the blending mass ratio (a) / (b) of the (a) virus inactivating component and the (b) virus inactivation efficacy enhancing component is 0.001≤(a) / (b)≤250, preferably 0.005≤(a) / (b)≤100, and more preferably 0.01≤(a) / (b)≤50, thereby achieving a virus inactivator composition capable of further improving the rapid effect of virus inactivation.

[0044] It is preferred that 10% to 80% by mass of (c) ethanol is further added to the virus inactivator composition of the present invention. By adding 10% to 80% by mass of (c) ethanol, the rapidity of virus inactivation can be improved. In addition, the dissipation of the virus inactivator composition is also improved, so that it becomes a virus inactivator composition with excellent quick-drying properties. Among them, it is preferred to add 35% to 65% by mass of (c) ethanol, and it is further preferred to add 55% to 65% by mass of (c) ethanol. By setting it to these amounts, the rapidity of virus inactivation can be more effectively improved, and skin irritation is less likely to occur during use. In addition, the dissipation of the virus inactivator composition is also effectively improved, so that it becomes a virus inactivator composition with excellent quick-drying properties.

[0045] If necessary, a surfactant may be added to the virus inactivating agent composition of the present invention. For example, a surfactant has the property of generating bubbles (foaming property), and therefore, if a surfactant with excellent foaming property is used, there are advantages that liquid dripping is suppressed when the virus inactivating agent composition of the present invention is sprayed onto a wall surface by trigger spraying (Japanese: Trigger Spray) or the like, and the coated area is also easily visually recognizable.

[0046] As the surfactant blended in the virus inactivator composition of the present invention, any of anionic surfactants, nonionic surfactants, and amphoteric surfactants can be appropriately used. The blending amount of the surfactant in the virus inactivator composition of the present invention is not particularly limited, but is preferably 0.1% by mass or more and 10% by mass or less. It should be noted that in this specification, the cationic virus inactivating component blended in the virus inactivator composition of the present invention is not included in the surfactant.

[0047] Examples of the anionic surfactant include fatty acid soaps, alkylbenzene sulfonates, linear alkylbenzene sulfonates, alkyl sulfates, α-olefin sulfonates, alkyl phosphate ester salts, polyoxyethylene alkyl ether sulfates, polyoxyethylene alkylphenyl ether sulfates, and polyoxyethylene alkyl ether phosphates.

[0048] Examples of nonionic surfactants include polyoxyethylene alkyl ethers, polyoxyethylene alkylphenyl ethers, polyoxyethylene higher fatty acid esters, polyoxyethylene sorbitan fatty acid esters, polyoxyethylene glycerol fatty acid esters, polyoxyethylene hydrogenated castor oil, coconut oil fatty acid diethanolamide, polyoxyethylene polyoxypropylene alkyl ethers, fatty acid alkanolamides, and alkylamine oxides.

[0049] Examples of amphoteric surfactants include betaine-type surfactants, specifically, lauryl-N,N-dimethylacetic acid betaine, laurylamidopropyl-N,N-dimethylacetic acid betaine, and coconut oil alkylamidopropyl-N,N-dimethylhydroxypropyl sulfobetaine.

[0050] The virus inactivator composition of the present invention is of an aqueous type, and mainly uses water as a solvent. Examples of water include purified water such as ion exchange water, reverse osmosis membrane water, ordinary tap water, industrial water, and deep sea water.

[0051] In addition, by adding antibacterial, virus inactivating agents, algae preventives, rust inhibitors, solvents, chelating agents, fragrances, deodorizing ingredients, pH adjusters, moisturizing ingredients, thickeners, etc. other than the cationic virus inactivating ingredients as other ingredients as necessary in the virus inactivating agent composition of the present invention within the range that does not impair the effects of the present invention, it is possible to impart antibacterial effects, virus inactivating effects, algae preventive effects, rust inhibitory effects, cleaning effects, fragrance, deodorizing properties, moisturizing effects, thickening effects, etc.

[0052] Examples of other antibacterial and virus inactivating agents include isopropyl methylphenol (IPMP), carvacrol, thymol, triclosan, methyl paraben, ethyl paraben, propyl paraben, butyl paraben, 4-chloro-3,5-dimethylphenol, o-phenylphenol, o-cresol, m-cresol, p-cresol, tebuconazole, enilconazole, grapefruit seed extract, persimmon seed extract, grape seed extract , monolaurin, monocapric glyceryl, monocaprylic glyceryl, benzoic acid, sorbic acid, glycine, alkyl diethylaminoglycine, polylysine, dehydroacetic acid, sodium dehydroacetate, chloramine, 3-iodo-2-propyl-N-butylcarbamate (IPBC), phenoxyethanol, silver zeolite, zinc pyrithione, thiamine dilauryl sulfate (Japanese: チアミンラウリルsulfate), protamine, hydroxyalkyl chitosan, chitosan, etc.

[0053] Examples of the algae preventive include sodium dichloroisocyanurate, and examples of the rust preventive include sodium benzoate.

[0054] Examples of the solvent include hydrocarbon solvents such as normal alkanes, isoalkanes, liquid paraffin, cycloalkanes, vaseline, squalane, and α-olefin oligomers; alcohol solvents such as 1-propanol, 2-propanol (IPA), 1-butanol, 2-butanol, tert-butanol, 1-pentanol, 1-hexanol, benzyl alcohol, and 2-phenylethanol; and glycol solvents such as 2-phenoxyethanol (ethylene glycol monophenyl ether), ethylene glycol, propylene glycol, 1-phenoxy-2-propanol (propylene glycol phenyl ether), 1,3-butanediol, propylene glycol monobutyl ether, dipropylene glycol monobutyl ether, and tripropylene glycol monobutyl ether.

[0055] Examples of the fragrance include d-limonene and other limonenes, α-pinene, β-pinene and other pinenes, cymene and other isopropyl toluenes, indene, caryophyllene and other hydrocarbon fragrances, linalool, geraniol, citronellol, menthols such as l-menthol, ethyl linalool, borneol, anisol, β-phenylethyl alcohol, p-menthane-3,8-diol, α-terpineol, γ-terpineol and other terpineols, 1-hexenol, cis-3-hexen-1-ol, tetrahydrogeraniol, sandalwood, cinnamyl alcohol, cedrol and other alcohol fragrances, galaxol, β-naphthyl methyl ether, eucalyptol, ambroxan, p-methyl anisole and other ether fragrances, anethole, eugenol, isoeugenol, vanillin, ethyl vanillin and other phenolic fragrances, octanal, nonanal, Undecanal, undecanal, decanal, n-butyraldehyde, isobutyraldehyde, hexanal, citral, citronellal, benzaldehyde, cinnamaldehyde, anisaldehyde, cuminaldehyde, adoc aldehyde, amyl cinnamaldehyde, cyclamen aldehyde and other aldehyde fragrances, ketone musk, carvone, menthone, camphor, camphor, acetophenone, butyrophenone, tonal musk, α-ionone, β-ionone, α-methylionone, β-methylionone, α-isomethylionone, β-isomethylionone, γ-methylionone, γ-isomethylionone, damascone (Japanese: ダマスコン), α-damascone, β-damascone, acetyl cedrene, cashmeran, cis-jasmone, dihydrojasmone and other ketone fragrances, γ-butyrolactone, γ-nonalactone, γ-decanolide, γ-undecalactone, Lactone fragrances such as coumarin, eucalyptol, malvaceae lactone, jasmine lactone, geranyl formate, octyl acetate, geranyl acetate, benzyl acetate, cinnamyl acetate, geranyl tetrahydroacetate, menthyl acetate, linalyl acetate, butyl propionate, benzyl acetate, methyl benzoate, allyl caproate, allyl heptanoate, allyl cyclohexanepropionate, allyl isopentyl acetate, amyl valerate, amyl salicylate, isopentyl acetate, butyl acetate, ethyl butyrate, acetyl eugenol, isopentyl salicylate, allyl caproate, ethyl caproate, ethyl propionate, ethyl acetoacetate, methyl salicylate, citronellyl acetate, vanillyl formate, cinnamyl acetate, stearyl acetate, stearyl propionate, cedar acetate, pine acetate and other ester fragrances, amyl cinnamaldehyde dimethyl acetal, lemon Acetal fragrances such as aldehyde dimethyl acetal, indole, lemon nitrile, citronella nitrile, acetaldehyde phenylethyl propyl acetate, benzonatate (Japanese: テサロン), nerolidol, linalool oxide, peppermint oil, orange oil, lemon oil, lavender oil, mint oil, eucalyptus oil, citronella oil, lime oil, grapefruit oil, jasmine oil, cypress oil, green tea essential oil, neroli oil, geranium oil, orange leaf oil, lemongrass oil, Cinnamon oil, lemon eucalyptus oil, thyme oil, perilla oil, pine oil, rose oil, rosemary oil, camphor oil, aromatic oil, sage oil, sandalwood oil, spearmint oil, star anise oil, lavender oil, oakmoss oil, sassafras oil (Japanese: オコチア oil), patchouli oil, tonka bean tincture, turpentine oil, vanilla bean tincture, basil oil, nutmeg oil, clove oil, rosewood oil, ylang-ylang oil,Cardamom oil, cinnamon oil, cedar oil, citrus oil, orange oil, fennel oil, bay leaf oil, coriander oil, elemi oil, fennel oil, gabardine oil, juniper oil, vetiver oil, bergamot oil, ylang-ylang oil, grapefruit oil, pine needle oil, celery oil (Japanese: アクジョン oil), almond oil, angelica root oil, sesame oil (Japanese: ページル oil), peppermint oil, birch oil, Kapok oil (Japanese: bobalognese oil), melaleuca oil (Japanese: kayabuchi oil), cananga oil (Japanese: gananga oil), chili oil, caraway oil, celery oil, konjac oil, cumin oil, jill oil (Japanese: dul oil), tarragon oil (Japanese: estogoran oil), garlic essential oil, ginger oil, hop oil, sage oil, turpentine, etc.

[0056] Examples of deodorizing ingredients include sugar cane extract, green tea extract, tea distillate, persimmon extract, grapefruit extract, bamboo extract, grapefruit seed extract, and forsythia extract. In addition to the deodorizing effect, sugar cane extract is preferred from the viewpoint of promoting the inactivation of norovirus.

[0057] Examples of the pH adjuster include other organic acids such as acetic acid, malic acid, and salicylic acid, other inorganic acids such as hydrochloric acid, sodium citrate, sodium carbonate, sodium hydrogen carbonate, and sodium hydroxide.

[0058] Examples of the moisturizing component include glycols such as glycerin, propylene glycol, and 1,3-butylene glycol, and polyols such as sorbitol.

[0059] Examples of thickeners include carboxyvinyl polymers of cross-linked polyacrylic acid, cellulose derivatives such as carboxymethyl cellulose, hydroxyethyl cellulose, and hydroxypropyl cellulose, xanthan gum, guar gum, gum arabic, sodium alginate, propylene glycol alginate, ethyl cellulose, sodium polyacrylate, and cyclodextrin.

[0060] The virus inactivating agent composition of the present invention thus obtained can be applied or sprayed on places where virus-infected persons have come into contact, places where vomitus of virus-infected persons has been handled, places contaminated with viruses such as clothes, etc., so that the virus can be effectively removed.

[0061] In addition, by applying or spraying the virus inactivating agent composition of the present invention on fingers or the like, viruses attached to fingers or the like can be effectively removed, thereby disinfecting the fingers.

[0062] In addition, the virus inactivating composition of the present invention has a high inactivation effect on non-enveloped viruses such as norovirus, rotavirus, rhinovirus, and adenovirus in addition to enveloped viruses such as influenza virus, coronavirus, and herpes virus. Therefore, it can also be suitably used for inactivating norovirus, which is difficult to inactivate with existing virus removing agents.

[0063] In addition, the virus inactivating agent composition of the present invention is composed of a cationic virus inactivating component as a virus inactivating component and a specific organic acid and / or inorganic acid as a virus inactivating effect enhancing component in water, and has a very simple composition. Therefore, the production is simple. In addition, there is no problem of discoloration caused by silver ions, so the usability is also excellent.

[0064] It should be noted that the present invention is not limited to the above-mentioned embodiments, and various changes can be made within the scope indicated in the claims, and the embodiments obtained by appropriately combining the technical means disclosed in different embodiments are also included in the technical scope of the present invention. The effects of the present invention are described in more detail below through examples, but the present invention is not limited by these examples.

[0065] [Example 1]

[0066] [Preparation of test solution]

[0067] (a) 1,4-bis(3,3'-(1-decylpyridinium)methoxy)dibromobutane (Hygenia S-100, manufactured by Tama Kagaku Industries, Ltd.), benzalkonium chloride (cation F2-50R, manufactured by NOF Corporation), benzethonium chloride (manufactured by FUJIFILM Wako Pure Chemical Industries, Ltd.), didecyldimethylammonium chloride (LIPOGARD210-80E, manufactured by Lion Specialty Chemicals Co., Ltd.), 20% chlorhexidine digluconate aqueous solution (manufactured by FUJIFILM Wako Pure Chemical Industries, Ltd.), (b) fumaric acid, phosphoric acid, lactic acid, citric acid monohydrate (the above, manufactured by FUJIFILM Wako Pure Chemical Industries, Ltd.), and (c) ethanol were blended in the blending ratios (mass %) shown in Tables 1 and 3, and purified water was added to make 100 mass % to obtain test solutions (present inventions 1 to 21).

[0068] (a) 1,4-bis(3,3'-(1-decylpyridinium)methoxy)dibromobutane (Hygenia S-100, manufactured by Tama Kagaku Industries, Ltd.), benzalkonium chloride (cation F2-50R, manufactured by NOF Corporation), benzethonium chloride (manufactured by FUJIFILM Wako Pure Chemical Industries, Ltd.), didecyldimethylammonium chloride (LIPOGARD210-80E, manufactured by Lion Specialty Chemicals Co., Ltd.), isopropylmethylphenol (manufactured by FUJIFILM Wako Pure Chemical Industries, Ltd.), (b) fumaric acid, phosphoric acid, lactic acid (the above, manufactured by FUJIFILM Wako Pure Chemical Industries, Ltd.), and (c) ethanol were blended in the blending ratios (mass %) shown in Tables 2 and 4, and purified water was added to give 100 mass % to obtain test solutions (Comparative Examples 1 to 15).

[0069] [Example 2]

[0070] [Confirmation test 1 of virus inactivation effect (Feline calicivirus)]

[0071] (Preparation of test virus solution)

[0072] CRFK cells (JCRB cell bank) were cultured in a monolayer in a tissue culture dish using a cell proliferation medium in which 10% fetal bovine serum was added to a MEM medium (manufactured by Nacalai Tesque Co., Ltd.). The cell proliferation medium was removed from the monolayer culture dish and feline calicivirus (Feline calicivirus F-9ATCC VR-782) was inoculated. Next, a cell maintenance medium in which 2% fetal bovine serum was added to the MEM medium was added and cultured in a carbon dioxide incubator (CO2 concentration 5%) at 37±1°C for 1 to 5 days. Feline calicivirus is a type of non-enveloped virus and is widely used as a substitute virus for norovirus that cannot be cultured in cells.

[0073] After the culture, the cell morphology was observed using an inverted phase contrast microscope, and morphological changes in the cells (cytopathic effect) were confirmed. Next, the culture solution was centrifuged at 1000 rpm / min for 3 minutes, and the obtained supernatant was ultrafiltered to prepare a test virus solution.

[0074] 0.1 mL of the test virus solution was added to 0.9 mL of the test solution of the present invention 1 to 10 and comparative examples 1 to 6 prepared in Example 1 to prepare the working solution. After 1 minute, the working solution was diluted 100 times with MEM culture medium to prepare a 10-fold dilution series. It should be noted that the same operation was performed on a solution in which the test virus solution was added to phosphate buffered saline as a control.

[0075] (Determination of Virus Infectious Titer)

[0076] Using cell proliferation medium, the cells were cultured in a monolayer in a tissue culture microplate (96 wells), then the cell proliferation medium was removed and 0.1 mL of cell maintenance medium was added each time. Next, 0.1 mL of a 10-fold dilution series of the action solution was inoculated into 4 wells each time and cultured in a carbon dioxide incubator (CO2 concentration 5%) at 37±1°C for 4 to 7 days. After culture, an inverted phase contrast microscope was used to observe the morphological changes of the cells (cytopathic effect), and the 50% cell culture infection dose (TCID) was calculated by the Reed-Muench method. 50 ), converted into infectious titer per 1 mL of the working solution, and compared with the infectious titer of purified water as a control, the logarithmic reduction value of the infectious titer was calculated.

[0077] The evaluation criteria for the virus removal effect were: x when the logarithmic reduction value of the infectivity titer was less than 1, △ when it was 1 or more and less than 1.5, ○ when it was 1.5 or more and less than 2, and ◎ when it was 2 or more. The evaluation results of the virus infectivity titer are shown in Tables 1 and 2 together with the composition of the test solution and the logarithmic reduction value of the infectivity titer.

[0078] [Table 1]

[0079]

[0080] [Table 2]

[0081]

[0082] As shown in Table 1, in the present inventions 1 to 10 containing (a) 0.01% to 5.0% by mass of any of 1,4-bis(3,3'-(1-decylpyridinium)methoxy)dibromobutane, benzalkonium chloride, benzethonium chloride, didecyldimethylammonium chloride and chlorhexidine digluconate as cationic virus inactivating components and (b) 0.02% to 10.0% by mass of any of fumaric acid, phosphoric acid and lactic acid, the logarithmic reduction value of the infectious titer against feline calicivirus was 1.5 or more, indicating a virus inactivating effect.

[0083] In particular, it was confirmed that in the present invention 3 in which the amount of 1,4-bis(3,3'-(1-decylpyridinium)methoxy)dibromobutane was set to 0.10 mass% and the amount of fumaric acid was set to 0.2 mass%, and in the present invention 5 in which the amount of 1,4-bis(3,3'-(1-decylpyridinium)methoxy)dibromobutane was set to 0.10 mass% and the amount of phosphoric acid was set to 0.2 mass%, the logarithmic reduction value of the infectious titer was greater than 3, and a better virus inactivation effect was obtained.

[0084] In contrast, as shown in Table 2, in Comparative Examples 5 and 6 in which only component (a) was added, and Comparative Examples 1 to 3 in which only component (b) was added, the logarithmic reduction value of the infectious titer for feline calicivirus was less than 1.5, and a sufficient virus inactivation effect was not confirmed. In addition, in Comparative Example 4 in which isopropylmethylphenol was used as another virus inactivation component instead of the cationic virus inactivation component of component (a), even if component (b) was used in combination, a rapid virus inactivation effect was not obtained, and no enhancement effect of component (b) was confirmed.

[0085] [Example 3]

[0086] [Confirmation test 2 of virus inactivation effect (Feline calicivirus)]

[0087] (Preparation of test virus solution)

[0088] CRFK cells (JRBC cell bank) were cultured in a tissue culture dish using a cell proliferation medium in which 10% fetal bovine serum was added to a MEM medium (manufactured by Nacalai Tesque Co., Ltd.). The cell proliferation medium was removed from the monolayer culture dish and feline calicivirus (Feline calicivirus F-9ATCC VR-782) was inoculated. Next, a cell maintenance medium in which 2% fetal bovine serum was added to the MEM medium was added and cultured in a carbon dioxide incubator (CO2 concentration 5%) at 37±1°C for 1 to 5 days.

[0089] After the culture, the cell morphology was observed using an inverted phase contrast microscope, and morphological changes in the cells (cytopathic effect) were confirmed. Next, the culture solution was centrifuged at 1000 rpm / min for 3 minutes, and the obtained supernatant was ultrafiltered to prepare a test virus solution.

[0090] 0.1 mL of the test virus solution was added to 0.9 mL of the test solution of the present invention 11 to 21 and comparative examples 7 to 15 prepared in Example 1 to prepare the working solution. After 20 seconds, the working solution was diluted 100 times with MEM culture medium to prepare a 10-fold dilution series. It should be noted that the same operation was performed on a solution in which the test virus solution was added to phosphate buffered saline as a control.

[0091] The method for measuring the virus infectivity titer and the evaluation criteria are the same as those in Example 2. The evaluation results of the virus infectivity titer are shown in Tables 3 and 4 together with the composition of the test solution and the logarithmic reduction value of the infectivity titer.

[0092] [Table 3]

[0093]

[0094] [Table 4]

[0095]

[0096] As shown in Table 3, it was confirmed that in the present inventions 11 to 21 containing (a) 0.01% to 5.0% by mass of any of 1,4-bis(3,3'-(1-decylpyridinium)methoxy)dibromobutane, benzalkonium chloride, benzethonium chloride, didecyldimethylammonium chloride and chlorhexidine digluconate as cationic virus inactivating components and (b) 0.02% to 10.0% by mass of any of fumaric acid, phosphoric acid, lactic acid and citric acid monohydrate, the logarithmic reduction value of the infectious titer for feline calicivirus was 2.5 or more, and a sufficient virus inactivation effect was shown 20 seconds after the treatment, indicating an excellent rapid virus inactivation effect.

[0097] In particular, it was confirmed that in the present invention 11 and the present invention 12 in which the blending amount of 1,4-bis(3,3'-(1-decylpyridinium)methoxy)dibromobutane was set to 0.10 mass % and the blending amount of fumaric acid was set to 0.04 mass % and 0.20 mass %, respectively, the blending amount of 1,4-bis(3,3'-(1-decylpyridinium)methoxy)dibromobutane was set to 0.10 mass % and the blending amount of phosphoric acid was set to 0.04 mass % and 0.20 mass %, respectively. In the present invention 13, the present invention 14 and the present invention 15 in which the dosage of 1,4-bis(3,3'-(1-decylpyridinium)methoxy)dibromobutane is set to 0.02 mass%, 0.03 mass% and 0.20 mass%, and in the present invention 17 in which the dosage of 1,4-bis(3,3'-(1-decylpyridinium)methoxy)dibromobutane is set to 0.10 mass% and the dosage of citric acid monohydrate is set to 0.20 mass%, the logarithmic reduction value of the infectious titer is greater than 3.0, and a more rapid virus inactivation effect is obtained.

[0098] In contrast, as shown in Table 4, in Comparative Examples 11 to 14 in which only component (a) was added, and Comparative Examples 7 to 9 in which only component (b) was added, the logarithmic reduction value of the infectious titer for feline calicivirus was less than 1.5, and a rapid viral inactivation effect was not sufficiently observed. In addition, in Comparative Example 10 in which isopropylmethylphenol was used as another viral inactivation component instead of the cationic viral inactivation component of component (a), a rapid viral inactivation effect was not obtained even when component (b) was used in combination, and no enhancement effect of component (b) was observed.

[0099] [Example 4]

[0100] [Confirmation test of virus inactivation effect 3 (Feline enteric coronavirus)]

[0101] (Preparation of test virus solution)

[0102] Feline fetus cells (fcwf-4: Feline catus whole fetus) were infected with feline enteric coronavirus, and when about 90% or more of the cell culture area showed cytopathic effect, they were stored in a -80°C refrigerator. Then, freeze-thaw operation was performed, and the supernatant after centrifugation at 3500 rpm for 10 minutes was concentrated by ultrafiltration membrane, and the obtained virus liquid was used as the sample virus.

[0103] 0.1 mL of the test virus solution was added to 0.9 mL of the test solution of the present invention 12 prepared in Example 1 to prepare the working solution. After 3 minutes, the working solution was diluted 100 times with MEM culture medium to stop the working process, and the resulting solution was used as the stock solution of the sample for measuring the infectivity titer, and the virus infectivity titer was measured. It should be noted that the same operation was performed on a solution in which the test virus solution was added to phosphate buffered saline as a control.

[0104] The results of the test show that in the sample for measuring the infectious titer after the virus inactivator composition of the present invention 12 was acted on, after 3 minutes, the feline coronavirus (Feline enteric coronavirus) was less than the detection limit, and the virus inactivator composition of the present invention 12 showed a virus inactivation effect on the feline coronavirus (Feline enteric coronavirus).

[0105] The present invention relates to a virus inactivating agent composition having excellent rapid effect in virus inactivation, a method for enhancing virus inactivation efficacy, and a virus inactivation method, and is particularly suitable for use as a virus inactivating agent composition applied by direct spraying or the like at a place contaminated by viruses.

Claims

1. A virus inactivator composition, It is characterized in that With: (a) 0.01% to 5.0% by mass of a cationic virus inactivating component as a virus inactivating component; (b) 0.02% to 10.0% by mass of one or more selected from fumaric acid, phosphoric acid, lactic acid and citric acid as a virus inactivation efficacy enhancing component; and water, (c) 10 to 80% by mass of ethanol is further added. The cationic virus inactivating component is one or more selected from didecyldimethylammonium salt, 1,4-bis(3,3'-(1-decylpyridinium)methoxy)butane salt, benzalkonium salt, benzyloxyethylammonium salt, and chlorhexidine salt.

2. The virus inactivator composition according to claim 1, It is characterized in that The cationic virus inactivating component is one or more selected from 1,4-bis(3,3'-(1-decylpyridinium)methoxy)dibromobutane, benzalkonium chloride, benzethonium chloride, didecyldimethylammonium chloride and chlorhexidine digluconate.

3. The virus inactivator composition according to claim 1 or 2, It is characterized in that The blending amount of the (c) ethanol is 35% by mass to 65% by mass.

4. The virus inactivator composition according to claim 1 or 2, It is characterized in that The blending mass ratio of the (b) virus inactivation efficiency enhancing component to the (a) virus inactivating component is (a) / (b) 0.001≤(a) / (b)≤250.

5. A method for enhancing the effectiveness of virus inactivation, It is characterized in that To a virus inactivator composition containing 0.01% to 5.0% by mass of a cationic virus inactivating component as (a) a virus inactivating component and water, 0.02% to 10.0% by mass of one or more selected from fumaric acid, phosphoric acid, lactic acid and citric acid as (b) a virus inactivating efficacy enhancing component is added, and 10% to 80% by mass of (c) ethanol is further added. The cationic virus inactivating component is one or more selected from didecyldimethylammonium salt, 1,4-bis(3,3'-(1-decylpyridinium)methoxy)butane salt, benzalkonium salt, benzyloxyethylammonium salt, and chlorhexidine salt.

6. A method for inactivating non-enveloped viruses for non-therapeutic purposes, comprising contacting the virus inactivating agent composition according to any one of claims 1 to 4 with the non-enveloped viruses.

Images